Company Encyclopedia
View More
name
Endovastec
688016.SH
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, and sale of aortic and peripheral vascular medical devices in China and internationally. The company’s products include branched aortic stent graft system, thoracic stent graft system, abdominal aortic stent graft and delivery system, bifurcated stent graft system, and other stent graft system in surgical operation, as well as accessories, such as balloon inflation catheter. Shanghai MicroPort Endovascular MedTech Co., Ltd.
354.40 B
688016.SHMarket value -Rank by Market Cap -/-

Financial Score

07/11/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking21/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE9.63%B
    • Profit Margin30.19%A
    • Gross Margin74.56%A
  • Growth ScoreD
    • Revenue YoY-1.32%D
    • Net Profit YoY-42.52%D
    • Total Assets YoY3.81%C
    • Net Assets YoY1.57%C
  • Cash ScoreC
    • Cash Flow Margin331.26%C
    • OCF YoY-1.32%D
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreA
    • Gearing Ratio15.85%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MICROPORT: Endovastec's net profit attributable to the parent company for the first three quarters is approximately 429 million yuan, a year-on-year decrease of 22.46%

    According to the Zhitong Finance APP, MICROPORT announced the performance of Endovastec for the first three quarters of 2025, with operating revenue of approximately 1.015 billion yuan, a year-on-year increase of 4.66%; net profit attributable to shareholders of the listed company was approximately 429 million yuan, a year-on-year decrease of 22.46%; basic earnings per share were 3.54 yuan

    Zhitong·
    HK
    00853
    -4.38%
    SH
    688016
    -1.10%
    Zhitong·
    HK
    00853
    -4.38%
    SH
    688016
    -1.10%

    Endovastec: Abdominal aortic stents officially enter clinical application in the Netherlands

    According to Endovastec, recently, the Minos®/Dinghaita™ abdominal aortic stent graft and delivery system completed its first two commercial applications in the Netherlands. The product was approved for market in China in 2019, received EU CE MDD certification in the same year, and was approved for EU CE MDR certification in 2025. It is currently in clinical use in nearly 30 countries across Europe, Asia, Latin America, and Africa

    Zhitong·
    SH
    688016
    -1.10%
    Zhitong·
    SH
    688016
    -1.10%

    Endovastec has repurchased a total of 1.2287 million shares, costing 129 million yuan

    According to the Zhitong Finance APP, Endovastec announced that as of August 31, 2025, the company has repurchased a total of 1,228,700 shares through the centralized bidding trading method (Phase II) via the Shanghai Stock Exchange trading system, with the highest transaction price being RMB 120.00 per share, the lowest price being RMB 84.26 per share, and the total amount of funds paid being RMB 129 million (excluding stamp duty, transaction commissions, and other transaction costs)

    Zhitong·
    SH
    688016
    -1.10%
    Zhitong·
    SH
    688016
    -1.10%

    MicroPort Medical: Endovastec's net profit attributable to the parent company in the first half of the year was approximately 315 million yuan, a year-on-year decrease of 22.03%

    According to the Zhitong Finance APP, MicroPort Medical announced the performance of Endovastec for the first half of 2025, with revenue of approximately 714 million yuan, a year-on-year decrease of 9.24%; the net profit attributable to the equity holders of Endovastec was approximately 315 million yuan, a year-on-year decrease of 22.03%

    Zhitong·
    SH
    688016
    -1.10%
    Zhitong·
    SH
    688016
    -1.10%

    Endovastec: The first clinical implantation of the Minos® abdominal aortic stent was completed in Libya

    According to Endovastec, recently, the company's Minos® abdominal aortic stent graft and delivery system successfully completed its first clinical implantation in Libya, marking the official entry of this product into clinical application in the country, and achieving another important breakthrough in the company's business expansion in the African market

    Zhitong·
    SH
    688016
    -1.10%
    Zhitong·
    SH
    688016
    -1.10%